• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.瑞莫拉宁对耐万古霉素革兰氏阳性菌的体外活性。
Antimicrob Agents Chemother. 1993 Jun;37(6):1364-6. doi: 10.1128/AAC.37.6.1364.
2
In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.万古霉素、替考拉宁、达托霉素、雷莫拉宁、MDL 62873及其他药物对葡萄球菌、肠球菌和艰难梭菌的体外活性。
J Antimicrob Chemother. 1990 Nov;26(5):627-33. doi: 10.1093/jac/26.5.627.
3
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.注射用链阳性菌素类抗生素RP59500对耐万古霉素革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1993 Mar;37(3):598-601. doi: 10.1128/AAC.37.3.598.
4
In vitro activity of RP 59500 (quinupristin/dalfopristin) and ramoplanin against vancomycin-resistant Enterococcus faecium.
Microb Drug Resist. 1995 Winter;1(4):335-9. doi: 10.1089/mdr.1995.1.335.
5
In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.瑞莫拉宁（一种新型脂糖肽）、万古霉素和替考拉宁对癌症患者革兰氏阳性临床分离株的体外活性。
J Antimicrob Chemother. 1996 Aug;38(2):265-9. doi: 10.1093/jac/38.2.265.
6
In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin.针对耐氨苄西林肠球菌和耐万古霉素革兰氏阳性菌测试的43种抗菌剂的体外活性。
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):337-45. doi: 10.1016/0732-8893(91)90025-b.
7
Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.雷莫拉宁对耐抗生素肠球菌的杀菌活性。
Antimicrob Agents Chemother. 1992 Oct;36(10):2342-5. doi: 10.1128/AAC.36.10.2342.
8
Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.替考拉宁、达托霉素、雷莫拉宁、万古霉素和PD127,391对革兰氏阳性球菌血液分离株的体外活性比较
Antimicrob Agents Chemother. 1992 Jul;36(7):1570-2. doi: 10.1128/AAC.36.7.1570.
9
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.雷莫拉宁、替考拉宁、万古霉素、利奈唑胺、杆菌肽及其他四种抗菌药物对肠道厌氧菌的体外活性
Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8. doi: 10.1128/AAC.47.7.2334-2338.2003.
10
In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.瑞莫拉宁、选定的糖肽类、氟喹诺酮类及其他抗生素对革兰氏阳性球菌临床血流分离株的体外活性。
Antimicrob Agents Chemother. 1993 Apr;37(4):896-900. doi: 10.1128/AAC.37.4.896.

引用本文的文献

1
Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria.环状脂肽：对抗耐药菌的新型抗菌药物。
Future Med Chem. 2013 Jul;5(11):1311-30. doi: 10.4155/fmc.13.86.
2
In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.雷莫拉宁、替考拉宁、万古霉素、利奈唑胺、杆菌肽及其他四种抗菌药物对肠道厌氧菌的体外活性
Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8. doi: 10.1128/AAC.47.7.2334-2338.2003.
3
Complexation of peptidoglycan intermediates by the lipoglycodepsipeptide antibiotic ramoplanin: minimal structural requirements for intermolecular complexation and fibril formation.脂糖缩肽抗生素瑞莫拉宁对肽聚糖中间体的络合作用：分子间络合和原纤维形成的最低结构要求
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7384-9. doi: 10.1073/pnas.102192099.
4
Vancomycin-resistant enterococci.耐万古霉素肠球菌
Clin Microbiol Rev. 2000 Oct;13(4):686-707. doi: 10.1128/CMR.13.4.686.
5
Current perspectives on glycopeptide resistance.糖肽类耐药性的当前观点
Clin Microbiol Rev. 1995 Oct;8(4):585-615. doi: 10.1128/CMR.8.4.585.
6
Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci.过氧化氢酶阴性革兰氏阳性球菌（不包括链球菌和肠球菌）的鉴定、分类及临床相关性
Clin Microbiol Rev. 1995 Oct;8(4):479-95. doi: 10.1128/CMR.8.4.479.
7
Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium.肽类抗生素对耐多药屎肠球菌的杀菌活性。
Antimicrob Agents Chemother. 1994 Feb;38(2):385-7. doi: 10.1128/AAC.38.2.385.
8
Comparison of agar dilution, tube dilution, and broth microdilution susceptibility tests for determination of ramoplanin MICs.用于测定雷莫拉宁最低抑菌浓度（MIC）的琼脂稀释法、试管稀释法和肉汤微量稀释法药敏试验的比较。
J Clin Microbiol. 1994 May;32(5):1364-5. doi: 10.1128/jcm.32.5.1364-1365.1994.
9
Rapid detection of vancomycin-resistant enterococci.耐万古霉素肠球菌的快速检测
J Clin Microbiol. 1994 Sep;32(9):2182-4. doi: 10.1128/jcm.32.9.2182-2184.1994.
10
Multidrug-resistant Enterococcus faecium. An untreatable nosocomial pathogen.耐多药屎肠球菌。一种无法治疗的医院病原体。
Drugs. 1994 Nov;48(5):678-88. doi: 10.2165/00003495-199448050-00003.

本文引用的文献

1
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.注射用链阳性菌素类抗生素RP59500对耐万古霉素革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1993 Mar;37(3):598-601. doi: 10.1128/AAC.37.3.598.
2
In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria.新型氟喹诺酮类药物CP-99,219对革兰氏阳性菌临床分离株的体外活性
Antimicrob Agents Chemother. 1993 Feb;37(2):366-70. doi: 10.1128/AAC.37.2.366.
3
Lactobacillus plantarum endocarditis in a patient with benign monoclonal gammopathy.
J Infect. 1988 Sep;17(2):127-30. doi: 10.1016/s0163-4453(88)91599-x.
4
In vitro evaluation of ramoplanin (A16686 or MDL62198). A new depsipeptide complex for potential topical use.瑞莫拉宁（A16686或MDL62198）的体外评估。一种潜在可用于局部给药的新型缩酚酸肽复合物。
Diagn Microbiol Infect Dis. 1989 May-Jun;12(3):279-82. doi: 10.1016/0732-8893(89)90029-1.
5
Inhibition of peptidoglycan biosynthesis by ramoplanin.雷莫拉宁对肽聚糖生物合成的抑制作用。
Antimicrob Agents Chemother. 1990 Mar;34(3):413-9. doi: 10.1128/AAC.34.3.413.
6
Vancomycin-resistant Pediococcus acidilactici: nine cases of bacteremia.耐万古霉素嗜酸乳杆菌：9例菌血症
J Infect Dis. 1990 May;161(5):956-60. doi: 10.1093/infdis/161.5.956.
7
Infection due to Leuconostoc species: six cases and review.明串珠菌属感染：6例病例及文献复习
Rev Infect Dis. 1990 Jul-Aug;12(4):602-10. doi: 10.1093/clinids/12.4.602.
8
Resistance of enterococci to glycopeptides.肠球菌对糖肽类抗生素的耐药性。
Antimicrob Agents Chemother. 1990 Dec;34(12):2291-6. doi: 10.1128/AAC.34.12.2291.
9
In vitro activity of 43 antimicrobial agents tested against ampicillin-resistant enterococci and gram-positive species resistant to vancomycin.针对耐氨苄西林肠球菌和耐万古霉素革兰氏阳性菌测试的43种抗菌剂的体外活性。
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):337-45. doi: 10.1016/0732-8893(91)90025-b.
10
Bactericidal activity of ramoplanin against antibiotic-resistant enterococci.雷莫拉宁对耐抗生素肠球菌的杀菌活性。
Antimicrob Agents Chemother. 1992 Oct;36(10):2342-5. doi: 10.1128/AAC.36.10.2342.

瑞莫拉宁对耐万古霉素革兰氏阳性菌的体外活性。

In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.

作者信息

Collins L A, Eliopoulos G M, Wennersten C B, Ferraro M J, Moellering R C

机构信息

Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.

出版信息

Antimicrob Agents Chemother. 1993 Jun;37(6):1364-6. doi: 10.1128/AAC.37.6.1364.

DOI:10.1128/AAC.37.6.1364
PMID:8328787
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC187967/
Abstract

In vitro activity of ramoplanin, a cyclic lipoglycopeptide, against 92 vancomycin-resistant gram-positive organisms was evaluated. Ramoplanin demonstrated potent activity against many highly vancomycin-resistant organisms including enterococci (MICs for 90% of strains tested of 0.5 micrograms/ml) and against Lactobacillus spp., Leuconostoc spp., and Pediococcus spp., all of which were inhibited at concentrations of < or = 0.25 micrograms/ml. This drug or a derivative compound merits further investigation as a potential therapeutic agent for infections due to vancomycin-resistant enterococci.

摘要

对环脂肽类药物瑞莫拉宁针对92株耐万古霉素革兰氏阳性菌的体外活性进行了评估。瑞莫拉宁对许多高度耐万古霉素的细菌表现出强效活性，包括肠球菌（90%受试菌株的MIC为0.5微克/毫升）以及乳酸杆菌属、明串珠菌属和片球菌属，所有这些菌在浓度≤0.25微克/毫升时均受到抑制。这种药物或其衍生化合物作为耐万古霉素肠球菌感染的潜在治疗药物值得进一步研究。